Dermapharm up after 9-month results beat forecasts

Dermapharm Holding SE

15/11/2023 08:12

** Shares in Dermapharm  DMPG.DE  rise 4% after the German
drugmaker reported 9-month results ahead of market expectations
    ** "A strong set of 9M figures with a 1.4% beat on topline
and 18.1% on adj. EBITDA vs. consensus," Jefferies says
    ** The company's consolidated revenue was up 18% at 866.6
million euros ($942.2 million), while adj. EBITDA rose 1.8% to
243.8 million euros, corresponding to a margin of 28.1%
    ** "All segments contributed to core growth with a strong
Arkopharma business contribution in 'other healthcare
products'," Jefferies says
    ** Dermapharm expects FY consolidated revenue and adj.
EBITDA to reach the upper range of its forecasts of 1.08-1.11
billion euros and 300-310 million euros, respectively
    ** Including Wednesday's rise, the stock has gained 7.7% YTD

($1 = 0.9198 euros)

 (Reporting by Mateusz Dobrzyniewski)
 ((Mateusz.dobrzyniewski@thomsonreuters.com))